SEC Tracker
Get the app

INSMED INSM

John Drayton Wise (Former Officer) plans to sell 20,000 INSM shares, about $2.1M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Jun 23, 2025
  2. Broker: Merrill Lynch
  3. Shares acquired by: Stock Plan Activity
  4. 10b5-1 plan adopted: Feb 27, 2024

All of John Drayton Wise's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when INSMED files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biogen BIIB public float $18.4B, Jun 30, 2025
  2. Teva Pharmaceutical Industries TEVA public float $18.2B, Jun 30, 2025
  3. BeOne Medicines ONC public float $14.7B, Jun 30, 2025
  4. United Therapeutics UTHR public float $11.2B, Jun 30, 2025
  5. Alnylam Pharmaceuticals ALNY public float $42.6B, Jun 30, 2025